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Impact on survival of the number of lymph
nodes resected in patients with lymph
node-negative gastric cancer
Xiaoyuan Chu1* and Zhong-Fa Yang2*
Abstract
Background: Patients with lymph node-negative gastric cancer show a better overall survival rate than those who
have a pathological lymph node-positive gastric cancer. But a large number of patients still develop recurrence. We
aimed to explore the significant prognostic factors of lymph node-negative gastric cancer and determine how
many lymph nodes should be removed.
Methods: A total of 3103 patients who underwent radical operation are identified from the Surveillance,
Epidemiology, and End Results database. Standard survival methods and restricted multivariable Cox regression
models were applied.
Results: The overall survival rate was significantly higher with an increasing number of negative lymph node
resected. Among the 843 patients who had the exact T stage, the overall survival rate was significantly better
in T3-4 group with more than 15 lymph nodes resected (P < 0.001) but not in T1-2 stage patients (P = 0.44). A
further 25 more lymph nodes resection did not show additional survival benefits. Multivariate analysis of patients
demonstrated that age, depth of tumor invasion, and the number of lymph nodes resected were the significant and
independent prognostic factors.
Conclusions: A lymphadenectomy with more than 15 lymph nodes removal should be performed for T3-4 lymph
node-negative gastric cancer. But the survival benefit of a lymphadenectomy with more than 25 lymph nodes
removal is disputed. And the further treatment should refer to the prognostic indicators.
Background
Gastric cancer is the fourth common malignant tumor
worldwide and the prognosis of this cancer remains poor
[1]. The 5-year overall survival rate is approximate 25 %
[2]. Nodal metastases in gastric cancer represent an im-
portant prognostic indicator after surgical resection, and
it is widely recognized that patients who received a stan-
dardized pattern of lymph node dissection may get more
survival benefits [3–5]. Although patients with lymph
node-negative gastric cancer show a better overall sur-
vival rate than those who have a pathological lymph
node-positive gastric cancer, recurrence occurred in a
large number of patients. Furthermore, little is known
about the prognostic factors in lymph node-negative
gastric cancer after radical surgery [6].
Several reports demonstrated that the depth of tumor
invasion is an independent prognostic factor of lymph
node-negative gastric cancer. But there is still contro-
versy on the prognostic significance of other factors,
such as patient age, tumor size, and patterns of lymph
node resection [6–9]. Meanwhile, the most recent edi-
tion (seventh) of the International Union against Cancer
(UICC) and the American Joint Committee on Cancer
(AJCC) do not define the necessary minimum number
of lymph nodes for resection, especially for gastric can-
cer patient at stage pN0. In this work, we evaluated the
prognostic factor of patients with lymph node-negative
gastric cancer. We further explored the optimal number
of lymph node resection for accurate staging and more
survival benefits in the patients with lymph node-
negative gastric cancer after radical dissection.
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Methods
Patients
The Surveillance, Epidemiology, and End Results (SEER)
program of the National Cancer Institute collected and
published cancer incidence and survival data from
population-based cancer registries. Data collected in-
clude patient demographic information, pathological
characteristics, and survival data from 1973 to 2009. The
exclusion criteria are (1) patients who did not have an
exact pathological diagnosis; (2) gastric cancer which
ICD-O-3 code without the range of 8000–8152, 8154–
8231, 8243–8245, 8250–8576, 8940–8950, and 8980–
8990; (3) patients who did not have an exact tumor size;
(4) patients who did not have an exact pathological
grade; (5) patients whose postoperative survival time was
less than 3 months; (6) patients with tumor location at
the esophagogastric junction (site code 160) were also
excluded to be consistent with the seventh edition of the
AJCC Cancer Staging Manual, which now stages these
patients under esophageal scheme; (7) patients with distant
metastasis; and (8) patients with no lymph node removed.
After screening patients with the above criteria, we ob-
tained a total of 3103 patient data sets with lymph node-
negative gastric cancer for further retrospective analysis.
Statistical methods
Patients with lymph node-negative gastric cancer were
classified into lymph node-negative group 1 (LNN 1) to
lymph node-negative group 4 (LNN 4) on the basis of
the following criteria: LNN 1, up to three (0–3) lymph
nodes removed; LNN 2, three to seven (3–7) lymph
nodes removed; LNN 3, seven to fifteen (7–15) lymph
nodes removed; LNN 4, more than fifteen lymph nodes
removed. These cutoff points were chosen by stratifying
patients into different groups with different numbers of
lymph nodes removed. The median survival times for
each LNN subgroup are as follows: 45 months for LNN
1, 50 months for LNN 2, 54 months for LNN 3, and
58 months for LNN 4. For tumor size, previous studies
used 5 cm as the cutoff point; we divided the group with
tumor size less than 5 cm into some more detailed sub
group in order to make a more accurate analysis. For
LNN groups, in Western countries and Eastern coun-
tries, different surgical methodologies are chosen. The
cutoff points are chosen according to AJCC metastatic
lymph node stages, we deem that a bit more lymph
nodes resected is the precondition to make an accurate
lymph node stage. Thus, four groups were established by
combining the neighborhood survival curves using the
log-rank test [10]. The exact T stage was determined
according to the seventh edition of the AJCC Cancer
Staging Manual and the corresponding SEER code.
Survival analysis and curves were calculated from
observed postoperative survival time according to the
Kaplan-Meier method and compared with the log-rank
test. Multivariate analyses were calculated in terms of
the Cox proportional hazard model. The chi-square
test was used to evaluate the statistical significance
of differences. Continuous data were presented as the
mean ± standard deviation (SD). Statistical analyses
were performed using SPSS 13.0 for windows. All statistical
tests were conducted two-sided, and P values <0.05 were
considered to be statistically significant.
Results
Patient characteristics
There were 3103 patients in the SEER database who ful-
filled the critical selection criteria between 1973 and
2009. Demographic and pathologic characteristics of
LNN 1 and LNN 4 were summarized in Table 1. In all
patients, 37,715 lymph nodes were examined (median 9,
mean 12.15, range 1–90). Median age was 73 years
(range 23–98). Among the 3103 patients, 1760 (56.7 %)
were males. One thousand eight hundred twenty of 3103
patients were white people, 446 were black, 19 were
indigenous populations of the Western hemisphere,
618 were East Asians (including Chinese, Japanese and
Korean), and the rest were 200 patients including
Filipino, Hawaiian, Vietnamese, Laotian, Kampuchean,
Thai, Asian Indian or Pakistani, Samoan and 3 unknown.
The tumor size was divided into six subgroups, and
most of them were less than 5 cm (n = 2197, 70.8 %).
For the tumor depth statistics, only 843 of the total 3103
patients got an exact AJCC T stage (only patients who
were diagnosed later than 2004 in the database have
enough details to make an accurate T stage according to
the AJCC seventh edition).
Overall survival analysis
The frequency distribution of examined lymph nodes for
the entire cohort of patients is shown in Fig. 1. The
overall survival rate of different LNN groups is shown in
Fig. 2. The overall survival rate was significantly higher
with an increasing number of negative lymph node
resected. The 5-year survival rate was 46 % for LNN 1
(patients with 1 to 3 negative lymph nodes removed)
compared with the rate of 56, 62, and 72 % for LNN 2,
LNN 3, LNN 4, respectively, those who had 4 to 7, 7 to
15 and more than 15 lymph nodes resected (P < 0.001).
We used Kaplan-Meier survival analysis to assess
seven prognostic factors: age, gender, race, tumor loca-
tion, tumor size, histopathological grade, and LNN
group. Univariate analysis and subsequent multivariate
analysis indicated that age, race, tumor size, and LNN
group were significant and independent prognostic fac-
tors after curative resection for lymph node-negative
gastric cancer (Table 2). Next, we extracted the data
after 2004 in order to assess the factor of the depth of
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tumor invasion. At this time, 843 patients were selected
and the result of the multivariate analysis confirmed that
age, depth of tumor invasion, and LNN group were sig-
nificant and independent prognostic factors (Table 3).
Furthermore, we collected patients with more than 15
lymph nodes removed for the sake of estimation of the
value of a more radical lymphadenectomy. Eight hun-
dred seventy-five patients were included according to
this criterion. According to the log-rank test result, it
did not show a significantly improved survival as a con-
tinued lymph nodes resection. A cutoff of 25 lymph
node resection was chosen for the analysis on the basis
of actual suggestions for the right number of nodes re-
trieved by a correct D2 dissection [11]. Figure 3 demon-
strated that the overall survival rate did not show a
significant difference between the patients with more
than 25 lymph nodes resected and patients with 15 to 25
lymph nodes resected (P = 0.345).
Table 1 Demographic and pathologic characteristics of LNN 1 to LNN 4
LNN 1 (n = 582) n (%) LNN 2 (n = 708) n (%) LNN 3 (n = 938) n (%) LNN 4 (n = 875) n (%)
Age (years)
≤65 133 (22.9 %) 189 (26.7 %) 274 (29.2 %) 311 (35.5 %)
>65 449 (77.1 %) 519 (73.3 %) 664 (70.8 %) 564 (64.5 %)
Gender
Male 311 (56.9 %) 419 (59.2 %) 531 (56.6 %) 479 (54.7 %)
Female 251 (43.1 %) 289 (40.8 %) 407 (43.4 %) 396 (45.3 %)
Race
White 392 (67.4 %) 460 (65.0 %) 527 (56.2 %) 441 (50.4 %)
Black 86 (14.8 %) 116 (16.4 %) 136 (14.5 %) 108 (12.3 %)
Indigenous Westerner 6 (1.0 %) 5 (0.7 %) 4 (0.4 %) 4 (0.5 %)
East Asian 73 (12.5 %) 100 (14.1 %) 195 (20.8 %) 250 (28.6 %)
Others 25 (4.3 %) 27 (3.8 %) 76 (8.1 %) 72 (8.2 %)
Location
Upper 20 (3.4 %) 28 (4.0 %) 43 (4.6 %) 39 (4.5 %)
Middle 50 (8.6 %) 67 (9.5 %) 102 (10.9 %) 126 (14.4 %)
Lower 241 (41.4 %) 290 (41.0 %) 407 (43.4 %) 298 (34.1 %)
Overlapping 271 (46.6 %) 323 (45.6 %) 386 (41.2 %) 412 (47.1 %)
Tumor size (cm)
Diameter ≤1 67 (11.5 %) 65 (9.2 %) 82 (8.7 %) 89 (10.2 %)
1< Diameter ≤2 120 (20.6 %) 137 (19.4 %) 164 (17.5 %) 125 (14.3 %)
2< Diameter ≤3 95 (16.3 %) 122 (17.2 %) 146 (15.6 %) 139 (15.9 %)
3 <Diameter ≤4 94 (16.2 %) 107 (15.1 %) 167 (17.8 %) 121 (13.8 %)
4< Diameter ≤5 70 (12.0 %) 88 (12.4 %) 97 (10.3 %) 102 (11.7 %)
Diameter >5 136 (23.4 %) 189 (26.7 %) 282 (30.1 %) 299 (34.2 %)
Depth of invasion
T0 and T1 54 (9.3 %) 71 (10.0 %) 123 (13.1 %) 129 (14.7 %)
T2 15 (2.6 %) 26 (3.7 %) 48 (5.1 %) 53 (6.1 %)
T3 24 (4.1 %) 43 (6.1 %) 78 (8.3 %) 84 (9.6 %)
T4 10 (1.7 %) 19 (2.7 %) 29 (3.1 %) 37 (4.2 %)
Unknown 479 (82.3 %) 549 (77.5 %) 660 (70.4 %) 572 (65.4 %)
Grade
Well differentiated 59 (10.1 %) 74 (10.5 %) 80 (8.5 %) 77 (8.8 %)
Moderately differentiated 217 (37.3 %) 250 (35.3 %) 346 (36.9 %) 265 (30.3 %)
Poorly differentiated 294 (50.5 %) 360 (50.8 %) 490 (52.2 %) 507 (57.9 %)
Undifferentiation 12 (2.1 %) 24 (3.4 %) 22 (2.3 %) 26 (3.0 %)
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Fig. 1 The frequency distribution of examined lymph nodes for the entire cohort of patients
Fig. 2 The overall survival curves of different LNN groups
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Subgroup analysis was then conducted to evaluate the
survival of the patients in different pathologic T categor-
ies (T1 + T2 and T3 + T4). For patients with T3 + T4
tumors, the overall survival rate was significantly differ-
ent between LNN subgroups (Fig. 4a). The overall sur-
vival rate in patients with T1 + T2 tumors had no
statistical difference (Fig. 4b). At the same time, evalu-
ation of the overall survival rate in different tumor size
Table 2 Univariate and multivariate predictors of overall survival
Univariate
analysis
Multivariate analysis
P value P value Hazard ratio
Age (years) <0.001 <0.001 2.015 (1.789–2.270)
≤65
>65
Gender 0.072
Male
Female
Race <0.001 <0.001 0.911 (0.878–0.945)
White
Black
Indigenous Westerner
East Asian
Others
Location 0.532
Upper
Middle
Lower
Overlapping
Tumor size (cm) <0.001 <0.001 1.006 (1.004–1.008)
Diameter ≤1
1< Diameter ≤2
2< Diameter ≤3
3< Diameter ≤4
4< Diameter ≤5
Diameter >5
Grade 0.066
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiation
Lymph node-negative group <0.001 <0.001 0.812 (0.777–0.849)
LNN 1
LNN 2
LNN 3
LNN 4
Table 3 Univariate and multivariate predictors of overall survival
(data late than 2004)
Univariate
analysis
Multivariate analysis
P value P value Hazard ratio
Age (years) <0.001 <0.001 2.194 (1.529–3.148)
≤65
>65
Gender 0.404
Male
Female
Race 0.01 0.724 0.981 (0.881–1.092)
White
Black
Indigenous Westerner
East Asian
Others
Location 0.74
Upper
Middle
Lower
Overlapping
Tumor size (cm) <0.001 0.896 1.000 (0.994–1.007)
Diameter ≤1
1< Diameter ≤2
2< Diameter ≤3
3< Diameter ≤4
4< Diameter ≤5
Diameter >5
Depth of invasion <0.001 <0.001 1.684 (1.463–1.937)
T0 and T1
T2
T3
T4
Grade 0.654
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiation
Lymph node-negative group 0.006 <0.001 0.773 (0.674–0.886)
LNN 1
LNN 2
LNN 3
LNN 4
Only those patients who are diagnosed late than 2004 in the database can get
enough details to make an accurate T stage according to the AJCC 7th edition
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Fig. 3 The overall survival curves of patients with more than 25 lymph nodes resected and patients with 15 to 25 lymph nodes resected
(log-rank test, P = 0.345)
Fig. 4 a The overall survival rate in patients with T3 + T4 tumors was significantly different between LNN subgroups. b The overall survival rate in
the patients with T1 + T2 tumors had no statistical difference
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categories indicated that the survival rate was signifi-
cantly better for patients with more than 15 lymph
nodes resected in all the tumor size subgroups.
Discussion
Our study was based upon rigorous analyses of the
previous studies about lymph node-negative gastric
cancer patients, thus excluding patients who died within
3 months after operation, patients who had an esopha-
gogastric or cardia cancer (site code C160), patients who
had distant metastasis, or patients who had no lymph
node resected. The reasons for this criteria setup are as
follows: (1) patients died within 3 months likely because
of surgical complications; (2) patients who had adeno-
carcinomas of esophagogastric junction were staged as
the esophageal scheme according to the AJCC seventh
edition; (3) if the gastric cancer had distant metastasis, it
would be a stage IV cancer regardless of the depth and
lymph node invasion; and (4) if a patient did not receive
the lymphadenectomy, it would be difficult to determine
whether the patient had nodal metastases.
Prognostic indicators for high recurrence rate at
univariate analysis were ages that were greater than
65 years, the white race, large tumors, deep depth of in-
vasion, and little lymph nodes removed. The association
between age and prognosis was hypothesized that elder
patients suffer from host immunodeficiency or malnutri-
tion [11, 12]. In our study, tumor location is not a prog-
nostic indicator for lymph node-negative gastric cancer.
But this factor is still in controversial. Xu et al. [9] and
Baiocchi et al. [11] reported that distal tumors were
associated with better prognosis due to a relatively late
presentation of the symptoms in proximal gastric cancer
[13]. Nevertheless, Lee et al. [14] did not find this
phenomenon. Although we divided the tumor location
into four groups: upper third, middle third, lower third,
and overlapping, we did not find its value to investigate
the prognosis. We further combined them into two sub-
types: distal gastric cancer and others, and we did not
find prognostic value either.
The SEER database is consisted of several registries
with different races. Our research indicated that in the
univariate analysis, race is a prognostic factor of lymph
node-negative gastric patients. The overall survival rate
of East Asian patients is better than others. This may be
due to the fact that East Asian surgeons routinely per-
form the D2 lymph node dissection while many Western
surgeons perform D1 lymph node dissection [15]. This
is supported by the number of lymph nodes resected,
combined with the fact that although all the patients
underwent D1 or D2 lymph node dissection, the pathol-
ogists and surgeons searched for lymph nodes in differ-
ent efforts and techniques, which could lead to omitted
lymph nodes in the specimen [16]. We can see from the
results that 40.5 % of East Asian patients received the
lymphadenectomy with more than 15 lymph nodes re-
moved, while only 24.2 % of the patients in the Western
world received the same type lymphadenectomy.
Tumor size failed to demonstrate a significant associ-
ation with overall rate in our series in the multivariate
analysis. However, the value of these prognostic factors
is still in controversial. Baiocchi et al. [11] and Lee et al.
[14] found that tumor size (cutoff 40 and 63 mm,
respectively) could not independently affect the overall
survival. By contrast, Xu et al. [7] indicated that tumor
size (cutoff 50 mm) was a strong prognostic factor
affecting the survival of lymph node-negative gastric
cancer patients. But in this study, tumor size range is an-
alyzed to homogenize the difference by choosing mul-
tiple cutoff points which is distinct from other studies
using only one cutoff point.
LNN groups, depth of tumor invasion, and ages are
independent prognostic indicators for lymph node-
negative gastric cancer. The four cutoff points for LNN
subgroups indicate that the more lymph nodes resected,
the better prognosis the patients can have. After extract-
ing the patients who received the lymphadenectomy
with more than 15 lymph nodes removed, however, we
found that a more extensive lymphadenectomy (more
than 25 lymph nodes resected) did not lead to better
survival. For different tumor size subgroups, the overall
survival rate among them has statistically significant dif-
ference when different lymph nodes were resected, even
in the less-than-1-cm group. This means that we cannot
judge the extent of lymph node dissection by the tumor
size. But for the different depth of invasive subgroups,
our study indicated that the overall survival rate for
T1 + T2 stage lymph node-negative gastric cancers has
no statistically significant difference, while it is statisti-
cally significant for the T3 + T4 subgroup. An alternative
explanation for this observation may be that patients
with T1 or T2 subcategories seldom spread to regional
lymph nodes. The incidence of lymph node metastasis in
T1 and T2 patients are less than 35 % [17–19]. However,
it is difficult to determine the depth of invasion and
lymph node metastasis before surgery. Recent studies
demonstrated that endoscopic ultrasonography has im-
proved the local accuracy in estimating the depth of
tumor invasion and lymph node involvement [20]. The
accuracy of endoscopic ultrasonography is better than
that of CT scan in determining the extent of infiltration
of the tumor. The accuracy ranges from 67 to 92 % [21].
Although the development of technology improves the
accuracy in determining the extent of infiltration of
gastric cancer, difficulty still remains in differentiating
the T2 stage from T3 stage [22]. A high-frequency (up
to 30 MHz) miniprobe-endoscopic ultrasonography,
which is able to demonstrate gastric wall up to nine
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different layers, can reach 100 % accuracy in identifying
the T1 gastric cancer. But the accuracy of endoscopic
ultrasonography is highly dependent on the experience
of the operators [22]. Therefore, we strongly suggest that
at least 15 lymph nodes be resected during the radical
operation.
Conclusions
In conclusion, although the lymph node-negative gastric
cancer has an excellent prognosis, some patients may
still have recurrence and die. Age, the number of lymph
nodes resected, and the depth of tumor invasion are the
prognostic factors to identify the lymph node-negative
patients who may receive significant benefit. Further
treatments should refer to these indicators. In addition,
our study suggests that a lymphadenectomy with more
than 15 lymph nodes removed should be performed. But
the survival benefit of a lymphadenectomy with 25 and
more lymph nodes resected is disputed, and it may need
some more evidence to prove its statistically significant
survival improvement.
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